All Stories

  1. Awareness of the link between human papillomavirus and oral cancer in UK university students
  2. Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data
  3. The impact of excluding or including Death Certificate Initiated (DCI) cases on estimated cancer survival: A simulation study
  4. Multizonal anogenital neoplasia in women: a cohort analysis
  5. Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses
  6. Reply to ‘Intraoperative radiotherapy for breast cancer: powerful evidence to change practice’
  7. Overdiagnosis in lung cancer screening
  8. Introducing human papillomavirus (HPV) primary testing in the age of HPV vaccination: projected impact on colposcopy services in Wales
  9. Exploring the impact of cancer registry completeness on international cancer survival differences: a simulation study
  10. The impact of COVID-19 disruption to cervical cancer screening in England on excess diagnoses
  11. A case-control study to evaluate the impact of the breast screening programme on mortality in England
  12. A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States
  13. Comparison of immediate colposcopy, repeat conventional cytology and high‐risk human papillomavirus testing for the clinical management of atypical squamous cells of undetermined significance cytology in routine health services of Medellin, Colombia: T...
  14. Intraoperative radiotherapy for early breast cancer — insufficient evidence to change practice
  15. Cancer Screening, Surrogates of Survival, and the Soma
  16. Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT
  17. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial
  18. Impact of changes to cervical screening guidelines on age and interval at which women are tested: Population-based study
  19. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial
  20. Can different definitions of date of cancer incidence explain observed international variation in cancer survival? An ICBP SURVMARK-2 study
  21. Lectins in Cervical Screening
  22. Evidence of HPV vaccination efficacy comes from more than clinical trials
  23. WELCOME-GP: A randomised controlled trial of the effectiveness of a targeted postal cancer awareness intervention for increasing attendance at general practice
  24. Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)
  25. Weekly COVID-19 testing with household quarantine and contact tracing is feasible and would probably end the epidemic
  26. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial
  27. Errors in determination of net survival: cause-specific and relative survival settings
  28. Population-level impact of human papillomavirus vaccination
  29. High-dose oral vitamin D supplementation and mortality in people aged 65–84 years: the VIDAL cluster feasibility RCT of open versus double-blind individual randomisation
  30. Development and validation of a risk prediction model to diagnose Barrett's oesophagus (MARK-BE): a case-control machine learning approach
  31. Impact of screening on cervical cancer incidence: A population‐based case–control study in the United States
  32. Cost‐effectiveness of e‐cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial
  33. Flexible use of flexible sigmoidoscopy
  34. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study
  35. Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts
  36. Equality and equity in medical screening: what is fair?
  37. E-cigarettes compared with nicotine replacement therapy within the UK Stop Smoking Services: the TEC RCT
  38. Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol
  39. A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method
  40. Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting
  41. Lung cancer mortality in Australia in the twenty-first century: How many lives can be saved with effective tobacco control?
  42. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome
  43. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy
  44. Cancer elimination thresholds: one size does not fit all
  45. Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer
  46. Impact of screening on cervical cancer incidence in England: a time trend analysis
  47. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany
  48. Is a delay in the introduction of human papillomavirus-based cervical screening affordable?
  49. Global perspectives surrounding cancer prevention and screening
  50. Barrett’s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux
  51. When should the errors in the UK's breast screening programme have been spotted?
  52. Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records
  53. Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study
  54. The acceptability of high resolution anoscopy examination in patients attending a tertiary referral centre
  55. Evaluation of Dried Blood Spots and Oral Fluids as Alternatives to Serum for Human Papillomavirus Antibody Surveillance
  56. The IARC Perspective on Colorectal Cancer Screening
  57. Trends and projections in adenocarcinoma and squamous cell carcinoma of the oesophagus in England from 1971 to 2037
  58. Acceptability of non-speculum clinician sampling for cervical screening in older women: A qualitative study
  59. Is the recent increase in cervical cancer in women aged 20–24 years in England a cause for concern?
  60. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study
  61. Cancer incidence in English children, adolescents and young people: past trends and projections to 2030
  62. What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study
  63. Systematic Review and Meta-Analysis of Individual Patient Data to Assess the Sensitivity of Cervical Cytology for Diagnosis of Cervical Cancer in Low- and Middle-Income Countries
  64. Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline
  65. Colorectal adenomas, surveillance, and cancer – Authors' reply
  66. Should a Reduction in All-Cause Mortality Be the Goal When Assessing Preventive Medical Therapies?
  67. Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions
  68. Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline
  69. Medicine is the ultimate personalised technology
  70. Urgent improvements needed to diagnose and manage Lynch syndrome
  71. Estimating the effect of treatment when patients in the control arm later take the new treatment
  72. Acceptability of the Cytosponge procedure for detecting Barrett's oesophagus: a qualitative study
  73. Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality
  74. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study
  75. Factors related to inter-observer reproducibility of conventional Pap smear cytology: a multilevel analysis of smear and laboratory characteristics
  76. Cancer risks in Nairobi (2000-2014) by ethnic group
  77. Cytology in the diagnosis of cervical cancer in symptomatic young women: a retrospective review
  78. Range of pathologies diagnosed using a minimally invasive capsule sponge to evaluate patients with reflux symptoms
  79. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case–control study
  80. On standardized relative survival
  81. By how much could screening by primary human papillomavirus testing reduce cervical cancer incidence in England?
  82. Offering self-sampling to cervical screening non-attenders in primary care
  83. Ovarian cancer screening: UKCTOCS trial
  84. Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?
  85. Impact of Screening on Breast Cancer Mortality—Response
  86. Performance characteristics of visualising the cervix in symptomatic young females: a review of primary care records in females with and without cervical cancer
  87. The age of cervical screening should be reduced
  88. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART
  89. Risk of preterm birth following surgical treatment for cervical disease: executive summary of a recent symposium
  90. Explaining the Better Prognosis of Screening-Exposed Breast Cancers: Influence of Tumor Characteristics and Treatment
  91. Impact of Screening on Breast Cancer Mortality: The UK Program 20 Years On
  92. Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy
  93. Analysis of trends is insufficient to posit the existence of two aetiological types of cervical cancer
  94. Response to Hersch et al.
  95. Black-white differences in cancer risk in Harare, Zimbabwe, during 1991-2010
  96. How many preterm births in England are due to excision of the cervical transformation zone? Nested case control study
  97. Cervical cytology and the diagnosis of cervical cancer in older women
  98. Interventions in randomised controlled trials in surgery: issues to consider during trial design
  99. MSLT ‐I: it's all about the lymph nodes…: reply from the authors
  100. Evaluating cytology for the detection of invasive cervical cancer
  101. Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records
  102. Are rigid management protocols stifling innovation in cancer treatment?
  103. clinical performance of the RNA based Aptima HPV test
  104. Informed Decision-Making and Breast Cancer Screening
  105. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis
  106. Reply to the letter to the editor ‘Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis’ by Louie et al.
  107. Is the increased risk of preterm birth following excision for cervical intraepithelial neoplasia restricted to the first birth post treatment?
  108. Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025
  109. Consultation rates in cervical screening non-attenders: opportunities to increase screening uptake in GP primary care
  110. Sentinel node biopsy in cutaneous melanoma: time for consensus to better inform patient choice
  111. Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Case–Control Studies
  112. Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960
  113. Visual Inspection after Acetic Acid (VIA) Is Highly Heterogeneous in Primary Cervical Screening in Amazonian Peru
  114. Evaluation of a Minimally Invasive Cell Sampling Device Coupled with Assessment of Trefoil Factor 3 Expression for Diagnosing Barrett's Esophagus: A Multi-Center Case–Control Study
  115. An ongoing case–control study to evaluate the NHS Bowel Cancer Screening Programme
  116. Estimating the workload associated with symptoms-based ovarian cancer screening in primary care: an audit of electronic medical records
  117. Risk of preterm delivery with increasing depth of excision for cervical intraepithelial neoplasia in England: nested case-control study
  118. C ox Regression Model
  119. Semiparametric Regression
  120. Delays in diagnosis of young females with symptomatic cervical cancer in England: an interview-based study
  121. Response to comment on ‘Characteristics and screening history of women diagnosed with cervical cancer aged 20–29’
  122. A prospective double-blind cross-sectional study of the accuracy of the use of dry vaginal tampons for self-sampling of human papillomaviruses
  123. The difference in sensitivity between HPV testing and cytology for detecting current and future CIN2+ increases over time
  124. Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years
  125. Cervical Screening at Age 50–64 Years and the Risk of Cervical Cancer at Age 65 Years and Older: Population-Based Case Control Study
  126. Survival Analysis
  127. An ongoing case-control study to evaluate the NHS breast screening programme
  128. New Strategies for Human Papillomavirus-Based Cervical Screening
  129. A pooled analysis of the outcome of prospective colonoscopic surveillance for familial colorectal cancer
  130. Characteristics and screening history of women diagnosed with cervical cancer aged 20–29 years
  131. How much could primary human papillomavirus testing reduce cervical cancer incidence and morbidity?
  132. Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia in a Single NHS Hospital
  133. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes
  134. HPV16 L1 and L2 DNA methylation predicts high‐grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology
  135. Reply to ‘Comment on Cancer incidence in the United Kingdom: projections to the year 2030’
  136. Characteristics of HPV infection over time in European women who are HIV-1 positive
  137. A Surveillance Model for Skin Cancer in Organ Transplant Recipients: A 22-Year Prospective Study in an Ethnically Diverse Population
  138. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus
  139. Dramatic increase in cervical cancer registrations in young women in 2009 in England unlikely to be due to the new policy not to screen women aged 20–24
  140. Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study
  141. Are women ready for the new cervical screening protocol in England? A systematic review and qualitative synthesis of views about human papillomavirus testing
  142. The impact of Jade Goody's diagnosis and death on the NHS Cervical Screening Programme
  143. Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study
  144. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model
  145. Screening mammography and socioeconomic inequalities in breast cancer survival
  146. Predictive Value of Symptoms for Ovarian Cancer: Comparison of Symptoms Reported by Questionnaire, Interview, and General Practitioner Notes
  147. Review of cytology and histopathology as part of the NHS Cervical Screening Programme audit of invasive cervical cancers
  148. 13. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010
  149. Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial
  150. Risk Factors for High-Risk Human Papillomavirus Infection and Cofactors for High-Grade Cervical Disease in Peru
  151. Cancer incidence in the United Kingdom: projections to the year 2030
  152. Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines
  153. Evaluation of the nationwide cervical screening programme in Thailand: a case-control study
  154. Single negative colposcopy: is it enough to rule out high-grade disease?
  155. What is the lifetime risk of developing cancer?: the effect of adjusting for multiple primaries
  156. Safe thresholds for hybrid capture 2 test in primary cervical screening
  157. Eurogin 2010 roadmap on cervical cancer prevention
  158. In defence of lifetime risk
  159. Epidemiology of gynaecological cancer
  160. Assessing Peanut Consumption in a Population of Mothers and Their Children in the UK
  161. ACOG Guidelines on Cervical Screening: A Step in the Right Direction
  162. Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy
  163. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study
  164. Has Cytology Become Obsolete as a Primary Test in Screening for Cervical Cancer?
  165. Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam)
  166. Modelling the likely effect of the increase of the upper age limit from 70 to 73 for breast screening in the UK National Programme
  167. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK
  168. What is the Right Age for Cervical Cancer Screening?
  169. Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)
  170. Further analysis of the ARTISTIC trial
  171. Screening and adenocarcinoma of the cervix
  172. Reply
  173. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data
  174. Prospective observational study: cervical cancer smears
  175. The potential for prevention of colorectal cancer in the UK
  176. Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls
  177. Household peanut consumption as a risk factor for the development of peanut allergy
  178. A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes
  179. How many cervical cancers are prevented by treatment of screen-detected disease in young women?
  180. Response to: Why young women should be screened for cervical cancer: The distinction between CIN2 and CIN3
  181. Predicting the impact of the screening programme for colorectal cancer in the UK
  182. Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy
  183. Cancer mortality in the United Kingdom: projections to the year 2025
  184. A deterministic model for estimating the reduction in colorectal cancer incidence due to endoscopic surveillance
  185. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study
  186. Cervical cancer prevention and hormonal contraception
  187. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC)
  188. Replication Timing Profile Reflects the Distinct Functional and Genomic Features of the MHC Class II Region
  189. Estimating the effect of treatment in a proportional hazards model in the presence of non-compliance and contamination
  190. Phenocopies in families seen by cancer geneticists
  191. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru
  192. Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: An international cohort study of cervical pathology in HIV-1 positive women
  193. Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses
  194. Cervical screening in 20–24-year olds
  195. Prospective Results of Surveillance Colonoscopy in Dominant Familial Colorectal Cancer With and Without Lynch Syndrome
  196. A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH
  197. Liquid-based versus conventional cervical cytology
  198. Call and recall cervical screening programme: Screening interval and age limits
  199. Chemoprevention of cervical cancer
  200. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
  201. Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission
  202. Overview of the European and North American studies on HPV testing in primary cervical cancer screening
  203. Methodological issues in international comparison of interval breast cancers
  204. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia
  205. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study
  206. A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe
  207. Cox Regression Model
  208. Semiparametric Regression
  209. Refining the Amsterdam Criteria and Bethesda Guidelines: Testing Algorithms for the Prediction of Mismatch Repair Mutation Status in the Familial Cancer Clinic
  210. Cervical screening in adolescents—at least do no harm
  211. Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin
  212. Reply: The value of case—control audits of screening
  213. The value of cervical screening to young women
  214. Promyelocytic leukemia nuclear bodies associate with transcriptionally active genomic regions
  215. Exposure to the sun and sunbeds and the risk of cutaneous melanoma in the UK: a case–control study
  216. Management of women who test positive for high-risk types of human papillomavirus: the HART study
  217. Martingale difference residuals as a diagnostic tool for the Cox model
  218. Evaluation of the UK breast screening programmes
  219. Outcomes of screening to prevent cancer: Think of screening as insurance
  220. The UK breast-screening programme should start at age 47 years
  221. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories
  222. Iterated residuals and time-varying covariate effects in Cox regression
  223. X-inactivation patch size in human female tissue confounds the assessment of tumor clonality
  224. On the Expected Number of Cancer Deaths During Follow-Up of an Initially Cancer-Free Cohort
  225. The Influence of Genetics and Environmental Factors in the Pathogenesis of Acne: A Twin Study of Acne in Women
  226. Could HPV testing become the sole primary cervical screening test?
  227. Adjusted Nelson–Aalen Estimates With Retrospective Matching
  228. How Many Mutations in a Cancer?
  229. A weighted Kaplan-Meier estimator for matched data with application to the comparison of chemotherapy and bone-marrow transplant in leukaemia
  230. Natural history of cervical human papillomavirus
  231. Routine audit is an ethical requirement of screening
  232. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England
  233. Genetics of Risk Factors for Melanoma: an Adult Twin Study of Nevi and Freckles
  234. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model
  235. Standardized Lifetime Risk
  236. Invited review. Statistical analysis of the performance of diagnostic tests
  237. Melanoma yield, number of biopsies and missed melanomas in a British teaching hospital pigmented lesion clinic: a 9-year retrospective study
  238. Supersites within superfolds. Binding site similarity in the absence of homology 1 1Edited by J. Thornton
  239. From Genotypes to Genes: Doubling the Sample Size
  240. Cervical sampling devices
  241. Risk factors for invasive cervix cancer in young women
  242. Effect of smoking cessation on cervical lesion size
  243. Full description of controls is needed in study
  244. Proportional excess hazards
  245. Dotplots
  246. Accelerated decline in cervical cancer mortality in England and Wales
  247. Non-Hodgkin's lymphoma and skin cancer
  248. Cervical screening: what is the point?
  249. Risks of second primary malignancy in patients with cutaneous and ocular melanoma in denmark, 1943–1989
  250. Risk of ocular melanoma in relation to cutaneous and IRIS naevi
  251. Efficiently weighted estimating equations with application to proportional excess hazards
  252. Endometriosis during tamoxifen treatment
  253. A partly parametric additive risk model
  254. Some New Estimators for Cox Regression
  255. A Partly Parametric Additive Risk Model
  256. Ingested Arsenic, Keratoses, and Bladder Cancer
  257. A note on the presentation of matched case-control data
  258. Information Bounds For the Additive and Multiplicative Intensity Models
  259. Correspondence Effect of Introducing A Restrictive Cervical Screening Policy On the Detection of Cervical Cancer
  260. Trends in cervical cancer mortality
  261. Cervical Screening
  262. Survival Analysis